Telephone
61.3.5445.5999
Address
27-33 Piper Lane East Bendigo, Victoria (VIC) 3550
Description
Apiam Animal Health Ltd. engages in the provision of genetics, veterinary services, wholesale, and retail of related products. It operates through the following business segments: Dairy Mixed, Feedlots, and Pigs. The firm offers veterinary production, technology, genetics, warehousing, logistics, and wholesale services. The company was founded by Christopher Richards in 1998 and is headquartered in East Bendigo, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.23 - 0.68
Trade Value (12mth)
AU$10,917.00
1 week
-5%
1 month
9.62%
YTD
-55.47%
1 year
-57.46%
All time high
1.85053
EPS 3 yr Growth
-63.600%
EBITDA Margin
8.90%
Operating Cashflow
$17m
Free Cash Flow Return
9.30%
ROIC
1.20%
Interest Coverage
4.50
Quick Ratio
0.60
Shares on Issue (Fully Dilluted)
178m
HALO Sector
Healthcare
Next Company Report Date
26-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Change of Registry Address
×
Change of Registry Address |
31 May 22 |
Presentation to the 20th Australasian AgFood Conference
×
Presentation to the 20th Australasian AgFood Conference |
31 March 23 |
Release of shares from voluntary escrow
×
Release of shares from voluntary escrow |
31 March 22 |
Release of shares from voluntary escrow
×
Release of shares from voluntary escrow |
31 August 23 |
Release of shares from voluntary escrow
×
Release of shares from voluntary escrow |
30 September 22 |
Board Renewal and key AGM dates
×
Board Renewal and key AGM dates |
30 November 23 |
Apiam at Coffee Microcaps Morning Meeting Webinar Series
×
Apiam at Coffee Microcaps Morning Meeting Webinar Series |
30 May 22 |
Entitlement Offer Update
×
Entitlement Offer Update |
30 May 22 |
Retail Entitlement Offer Booklet
×
Retail Entitlement Offer Booklet |
30 March 22 |
AHX secures viral vaccine lab funding
×
AHX secures viral vaccine lab funding |
30 January 23 |
Strategic NSW acquisitions into two new high-growth regions
×
Strategic NSW acquisitions into two new high-growth regions |
30 January 23 |
Proposed issue of securities - AHX
×
Proposed issue of securities - AHX |
30 August 21 |
FY2021 Appendix 4E and Annual Report
×
FY2021 Appendix 4E and Annual Report |
30 August 21 |
FY2021 Results Presentation
×
FY2021 Results Presentation |
29 October 18 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 November 18 |
Managing Director's Presentation to Shareholders
×
Managing Director's Presentation to Shareholders |
29 November 18 |
Results of 2018 Annual General Meeting
×
Results of 2018 Annual General Meeting |
29 August 22 |
FY22 Appendix 4E and Annual Report
×
FY22 Appendix 4E and Annual Report |
29 August 22 |
Dividend/Distribution - AHX
×
Dividend/Distribution - AHX |
29 August 22 |
FY22 Results Release
×
FY22 Results Release |
29 August 22 |
FY22 Investor Presentation
×
FY22 Investor Presentation |
29 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 April 22 |
Investor Update
×
Investor Update |
28 November 19 |
Managing Director's Presentation to Shareholders
×
Managing Director's Presentation to Shareholders |
28 November 19 |
Results of 2019 Annual General Meeting
×
Results of 2019 Annual General Meeting |
28 June 22 |
Change in substantial holding
×
Change in substantial holding |
28 January 22 |
Application for quotation of securities - AHX
×
Application for quotation of securities - AHX |
28 January 22 |
Issue of securities
×
Issue of securities |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.